Brought to you by 
TPG sells Par Pharmaceutical to Endo for $8bn
19 Sep 2017
Executive Summary
In its biggest takeover to date, Endo International PLC acquired privately held Par Pharmaceutical Holdings Inc. for $8bn, including assumed debt. Endo will issue 18mm shares (worth $1.5bn) and pay $6.5bn in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
- Nasal
- Transdermal
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com